Abstract
In the last two decades or so the intramuscular administration of botulinum toxin type A, and more recently type B, has become an established first line treatment of many neurological and other medical disorders. So far, the toxin has been used mainly by experienced researchers and clinicians with extensive knowledge of its mode of action and potential adverse effects. However, in the foreseeable future it is likely that this treatment will be provided by more medical practitioners and in different clinical settings, especially as the range of its clinical indications increases. Botulinum toxin, in therapeutic doses, is a remarkably safe drug with relatively few adverse effects. The commonest adverse effects are muscle weakness, fatigue, flu-like symptoms, a dry mouth, dizziness and a skin rash. Nonetheless, serious adverse events may occur, albeit rarely, and it is imperative that prescribers of this treatment are thoroughly familiar with its potential risks. The purpose of this article is to review the possible adverse effects of botulinum toxin intramuscular injections, to describe the factors that might predispose to them and to summarise the strategies for their prevention and treatment.
Keywords: Botulinum toxin., adverse events, drug safety
Current Drug Safety
Title: The Possible Adverse Effects of Intramuscular Botulinum Toxin Injections and their Management
Volume: 1 Issue: 3
Author(s): A. Magid O. Bakheit
Affiliation:
Keywords: Botulinum toxin., adverse events, drug safety
Abstract: In the last two decades or so the intramuscular administration of botulinum toxin type A, and more recently type B, has become an established first line treatment of many neurological and other medical disorders. So far, the toxin has been used mainly by experienced researchers and clinicians with extensive knowledge of its mode of action and potential adverse effects. However, in the foreseeable future it is likely that this treatment will be provided by more medical practitioners and in different clinical settings, especially as the range of its clinical indications increases. Botulinum toxin, in therapeutic doses, is a remarkably safe drug with relatively few adverse effects. The commonest adverse effects are muscle weakness, fatigue, flu-like symptoms, a dry mouth, dizziness and a skin rash. Nonetheless, serious adverse events may occur, albeit rarely, and it is imperative that prescribers of this treatment are thoroughly familiar with its potential risks. The purpose of this article is to review the possible adverse effects of botulinum toxin intramuscular injections, to describe the factors that might predispose to them and to summarise the strategies for their prevention and treatment.
Export Options
About this article
Cite this article as:
Bakheit O. A. Magid, The Possible Adverse Effects of Intramuscular Botulinum Toxin Injections and their Management, Current Drug Safety 2006; 1 (3) . https://dx.doi.org/10.2174/157488606777934431
DOI https://dx.doi.org/10.2174/157488606777934431 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Meet the Guest Editor
Combinatorial Chemistry & High Throughput Screening Management of Hypertension in the Acute Phase of Stroke
Current Hypertension Reviews Genetics of Polygenic Hypertension from Animal Models to Humans
Current Hypertension Reviews The Synthetic Cannabinoids Phenomenon
Current Pharmaceutical Design Contemporary Pharmacologic Management of Heart Failure with Reduced Ejection Fraction: A Review
Current Cardiology Reviews Diabetes Mellitus: Novel Insights, Analysis and Interpretation of Pathophysiology and Complications Management with Imidazole-Containing Peptidomimetic Antioxidants
Recent Patents on Drug Delivery & Formulation A Review Study about the Effect of Chitosan Nanocarrier on Improving the Efficacy of Amphotericin B in the Treatment of Leishmania from 2010 to 2020
Current Drug Delivery Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus
Current Pharmaceutical Design Treatment of Hypertensive Complications in Pregnancy
Current Pharmaceutical Design HIF Prolyl-4-hydroxylase Interacting Proteins: Consequences for Drug Targeting
Current Pharmaceutical Design Phospholipase A2 Myotoxins from Bothrops Snake Venoms: Structure- Function Relationship
Current Organic Chemistry Pathogenesis-Oriented Targets for Adjunctive Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Current Pharmaceutical Treatments and Alternative Therapies of Parkinson’s Disease
Current Neuropharmacology RAAS Inhibition and Renal Protection
Current Pharmaceutical Design Regulation of Blood Pressure by D5 Dopamine Receptors
Cardiovascular & Hematological Agents in Medicinal Chemistry Exercise as Treatment for Neuropathy in the Setting of Diabetes and Prediabetic Metabolic Syndrome: A Review of Animal Models and Human Trials
Current Diabetes Reviews Sedation in PACU: The Role of Propofol
Current Drug Targets Monoclonal Antibodies: A New Era in the Treatment of Non-Hodgkins Lymphoma
Current Pharmaceutical Biotechnology The Phospholipase A2 Homologues of Snake Venoms: Biological Activities and Their Possible Adaptive Roles
Protein & Peptide Letters Role of Heme Oxygenase-1 in Vascular Disease
Current Pharmaceutical Design